Seven top independent companies forge alliance to tackle Orphan Drug access across Asia Pacific

In Market Access, Partnering & Investment by Simon Reid

Orphan Asia 2

18th June marks the day of the formation of the Asia Pacific Orphan Drug Alliance (APODA).  It was formally announced during World Orphan Drug Congress Asia 2013.

Currently, it has been noted that not many orphan drug reach Asia Pacific patients due to various challenges such as regulatory complexity, low perceived sales opportunity and high commercial barriers.  APODA aims to bring together the different Biotechs in the orphan drug industry to provide solutions for 10 markets and 1.8 billion orphan drug patients.

“APODA is the ideal solution for Biotech companies wishing to remain independent from big Pharma but still gain access to Asia Pacific” said Giles Moss, Director of AFT Pharma.

Click here to download the press release to find out more!